Antigen-Bound Solid Support for Therapeutic Antibody Removal
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for monitoring multiple myeloma patients treated with therapeutic monoclonal antibodies like daratumumab and elotuzumab interfere with the detection of disease-related antibodies due to similar electrophoretic properties, leading to misclassification of treatment efficacy and remission status.
Innovation Solution
A method involving a solid support with antigens specific to therapeutic monoclonal antibodies, such as CD38 and SLAMF7, is used to bind and remove these antibodies from biological samples, allowing for accurate detection of disease-related antibodies using electrophoretic methods.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If therapeutic monoclonal antibodies are detected using standard electrophoretic methods, then treatment monitoring is performed, but false positive detection of M-protein occurs due to similar electrophoretic properties
Solution Approach 1:
The patent extracts and removes therapeutic monoclonal antibodies from the biological sample before performing electrophoretic detection of M-protein. This is achieved by incubating the sample with solid supports bearing antigens specific to the therapeutic antibodies (CD38 for daratumumab, SLAMF7 for elotuzumab), causing the therapeutic antibodies to bind to the solid supports and be removed from solution, thereby eliminating their interference with subsequent M-protein detection
Solution Approach 2:
The patent introduces solid supports with specific antigens as intermediary substances that mediate the selective binding and removal of therapeutic monoclonal antibodies. These solid supports act as intermediaries between the therapeutic antibodies and the detection system, allowing specific capture of therapeutic antibodies while leaving M-protein untouched for accurate detection
2Measurement precision
If standard electrophoretic methods are used to monitor multiple myeloma patients, then treatment response assessment is performed, but misclassification of remission status occurs due to presence of therapeutic antibodies
Solution Approach 1:
The patent extracts therapeutic monoclonal antibodies from the sample using antigen-specific solid supports, removing the source of misinterpretation before electrophoretic analysis. This extraction step ensures that only endogenous M-protein levels are measured, enabling accurate assessment of remission status without contamination from therapeutic antibody signals
Solution Approach 2:
The patent implements a feedback mechanism where the detection system is adjusted based on the presence of therapeutic antibodies. By first detecting or inferring therapeutic antibody presence and then applying selective removal, the system feedback-corrects the measurement process to eliminate misclassification of remission status
3Reliability
If antigen-specific solid supports are used to remove therapeutic antibodies, then accurate M-protein detection is achieved, but additional sample preparation steps are required
Solution Approach 1:
The patent extracts therapeutic antibodies using solid supports that can be easily added to and removed from liquid samples. The solid supports are incubated with the sample, bound antibodies are washed away, and the cleaned sample is transferred to electrophoresis, creating a simple extractive purification step that integrates smoothly into existing workflows
Solution Approach 2:
The patent develops universal solid support reagents that can remove multiple different therapeutic monoclonal antibodies (daratumumab, elotuzumab, and potentially others) using the same basic mechanism. This multi-functionality reduces the need for multiple specialized reagents and simplifies the overall process across different treatment scenarios
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This approach effectively removes therapeutic monoclonal antibodies, enabling accurate diagnosis and monitoring of disease status in patients, reducing interference and misclassification, and is applicable across various platforms without requiring expensive equipment or specialized expertise.
Implementation Method 1
contacting the biological sample with a solid support having one or more antigens bound thereto, which antigens bind the one or more therapeutic monoclonal antibodies
Implementation Method 2
detecting the disease-related antibody in the biological sample using an electrophoretic method
Data Source
AI summary
Disclosed herein are compositions and uses thereof for detection of disease-related antibodies. The methods include contacting a biological sample with a solid support comprising one or more antigens that bind one or more therapeutic monoclonal antibodies, and detecting the disease-related antibody in the biological sample using an electrophoretic method.